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A novel Plasmodium falciparum gene, MB2, was iden-
tified by screening a sporozoite cDNA library with the
serum of a human volunteer protected experimentally
by the bites of P. falciparum-infected and irradiated
mosquitoes. The single-exon, single-copy MB2 gene is
predicted to encode a protein with an Mr of 187,000. The
MB2 protein has an amino-terminal basic domain, a cen-
tral acidic domain, and a carboxyl-terminal domain
with similarity to the GTP-binding domain of the pro-
karyotic translation initiation factor 2. MB2 is expressed
in sporozoites, the liver, and blood-stage parasites and
gametocytes. The MB2 protein is distributed as a ;120-
kDa moiety on the surface of sporozoites and is im-
ported into the nucleus of blood-stage parasites as a
;66-kDa species. Proteolytic processing is favored as
the mechanism regulating the distinct subcellular local-
ization of the MB2 protein. This differential localization
provides multiple opportunities to exploit the MB2 gene
product as a vaccine or therapeutic target.
Plasmodium falciparum is the most virulent etiological
agent of human malaria, responsible for over 90% of mortality
due to the disease. Each year 300–500 million people are in-
fected by malaria parasites, and this results in 1.5–3 million
deaths (1). Efforts to eradicate malaria generally have failed,
and currently the disease is endemic in more than 90 countries
throughout the tropics. Widespread and increasing drug and
insecticide resistance have exacerbated the situation, under-
mining the effectiveness of existing malaria control methods
that depend on chemotherapy and vector control, respectively.
Novel means to fight the disease are needed urgently, and a
vaccine is predicted to have the greatest impact in addition to
being the most cost-effective control measure (2).
Experimental support for the development of a vaccine for
human malaria was provided first by the use of radiation-
attenuated sporozoites as immunogens (3). The success of this
experimental vaccination provided the impetus for the search
for mechanisms of protective immune responses and the target
antigens involved. The circumsporozoite (CS) protein was iden-
tified as the major surface antigen of Plasmodium sporozoites
(4–6). The CS protein has been a leading vaccine candidate
antigen because irradiated sporozoite-induced, protected hu-
man volunteers have high titers of anti-CS1 antibodies (7), and
CS-specific monoclonal antibodies and cytotoxic T-lymphocytes
could adoptively transfer protection in a rodent malaria model
system (8). However, attempts to induce protection in humans
using P. falciparum CS-based vaccines, despite recent improve-
ment in their immunogenicity, have repeatedly yielded only
partial success (9–13).
The inability to develop a vaccine based on the CS protein
was interpreted to indicate that additional antigens play a
role in irradiated sporozoite-mediated protection against in-
fection (14). It then becomes important to identify antigens
that may act independently, additively or synergistically
with the CS protein in the development of a multicomponent
vaccine. Here we report the characterization of MB2, a novel
gene encoding a P. falciparum sporozoite surface antigen
identified by screening a CS-depleted sporozoite expression
cDNA library with serum from a human volunteer protected
by the bites of P. falciparum-infected and irradiated mosqui-
toes. The MB2 gene is expressed in sporozoites, the exoeryth-
rocytic stages, the asexual blood stages, and gametocytes, but
the gene product is localized differentially in these develop-
mental stages. This differential localization provides multi-
ple opportunities to exploit the MB2 gene product as a vac-
cine and drug target.
EXPERIMENTAL PROCEDURES
Library Construction—A CS-depleted sporozoite cDNA library was
constructed from a P. falciparum salivary gland sporozoite cDNA
library (strain NF54; Ref. 15) using a hydroxyapatite column-based
subtractive hybridization technique (16). Briefly, to prepare the tar-
get cDNA sense-strands, DNA from the unsubtracted library was
linearized with NotI and used as a template to transcribe antisense
cRNAs with T7 RNA polymerase (Megascript, Ambion). Template
DNA was removed by DNase treatment and the antisense cRNA
strands were used to generate cDNA sense strands in a reaction using
SuperScript (Life Technologies, Inc.) reverse transcriptase. To pre-
pare the driver cRNA, a CS clone, G89 (17), was linearized with NotI.
Digestion products were used to generate antisense CS cRNA with T7
RNA polymerase (Megascript, Ambion).
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The target cDNA sense strands were allowed to reassociate with a
50-fold excess of the driver cRNA antisense strands. The reassocia-
tion mix was loaded onto a hydroxyapatite column and non-duplex,
single-stranded target cDNA was separated from duplex cDNA/cRNA
by elution with a high molarity phosphate buffer. Primers specific for
the UniZap l phage vector (Stratagene) were used to amplify the
subtracted cDNA, and the amplification products were subcloned into
the phage arms of the UniZap vector and packaged.
Library Screening—Phage were plated and lifted onto nitrocellulose
membranes that were soaked in 10 mM isopropylthio-b-D-galactoside
and air-dried prior to use. Membranes were incubated in the serum of
human volunteer 52 at a 1:100 dilution, and horseradish peroxidase-
conjugated anti-human IgG1IgM were used to detect positive antibody
reactions by the ECL system (Amersham Pharmacia Biotech). Positive
phage were screened a second time to isolate single phage clones.
Additional cDNA and genomic clones (strain ITO) were recovered using
MB2-derived 32P-labeled probes and standard library-screening tech-
niques (18).
DNA Sequencing of MB2—The primary nucleotide sequences of all
clones were determined by the dideoxynucleotide chain termination
method (19) using a 33P nucleotide terminator kit (Amersham Pharma-
cia Biotech). Specific oligonucleotide primers for sequencing were made
by Heligen Laboratories (Huntington Beach, CA). Contiguity of clones
was verified by gene amplification of genomic DNA using the following
primers: a, 59-GGTGATGACATTGAAGATATGAATG-39; b, 59-CAATA-
GAATAGATATAATCACC; c, 59-CTGGGTCATCATATGGAAAAGTG-
39; and d, 59-CAATACACCCTGCAACCTTTCC-39.
Southern and Northern Analyses—P. falciparum genomic DNA was
isolated using a phenol/chloroform-based procedure (18) from blood-
stage parasites (strain FCR3) cultured in vitro. The DNA was digested
with various restriction endonucleases, and Southern blots were pre-
pared as described (18). The probe for Southern blot analyses was
prepared by labeling the sporozoite cDNA clone, spz-MB2, with radio-
active [32P]ATP using the Megaprime DNA system (Amersham Phar-
macia Biotech). Total RNA was isolated from blood-stage parasites of
the same strain cultured in vitro using the Trizol® reagent (Life Tech-
nologies, Inc.). 15–20 mg of total RNA were electrophoresed and North-
ern blots were prepared as described (18). Two 32P-labeled probes
consisting of nucleotides 1–580 and 2393–2836 of the coding sequence of
MB2 were used separately on filters to which RNA from blood-stage
parasites had been transferred.
Recombinant Protein Expression and Purification—Segments of the
MB2 open reading frame (ORF) were expressed in bacteria as GST-
MB2–6xHis fusion proteins from the dual-affinity expression vector,
pAK1–6H (20). NcoI and SmaI cloning sites were created for each
insert by amplifying NF54 strain genomic DNA. The primer pair, 59-G-
ATGCCATGGAATATAATAGAATATGCTCA-39 and 59-GATCCCGGG-
TTTTTATTATTAGAAGAATCA-39, was used to amplify a sequence that
encodes a peptide, designated MB2-B, that overlaps amino acids (aa)
95–206. The primer pair, 59-GATGCCATGGATTCTTCTAATAATAAA-
AAT-39 and 59-ATGCATCCCCGGGTCATTTTTTATTTGAAGAATTCT-
C-39, was used to amplify a sequence that encodes a second peptide,
designated MB2-C, that overlaps aa 200–316. The primer pair, 59-GT-
ATGCCATGGTCCACGAAAATAAAGAATATAATTCAAG-39 and 59-G-
ATCCCGGGTCATCGAGCGATTCATTTTGGTC-39, was used to
amplify a sequence encoding the peptide, MB2-FA, that overlaps aa
764–945. Finally, the primer pair, 59-GATGCCATGGATGG TAATAG-
AACAAATAATGAC-39 and 59-GATCCCGGGTACGCTTCGATTATAT-
CGTTTGGCTC-39, was used to amplify a sequence that encodes the
peptide, MB2-IF2, that overlaps aa 1337–1606. The amplification prod-
ucts were digested with NcoI and SmaI and ligated into pAK1–6H. The
ligation mixture was used to transform Escherichia coli DH10B, and
transformants were selected. Bacterial cells were grown at 37 °C in
SuperBroth (Life Technologies, Inc.) to an A600 5 0.6 and induced in 1
mM final concentration of isopropylthio-b-D-galactoside for 3–4 h to
express recombinant proteins. Purification of recombinant proteins was
done using the ProBond resin (Invitrogen) modified by the inclusion of
imidazole at 85 mM final concentration in the washing buffer. Eluted
fractions were analyzed for the presence of recombinant proteins by
SDS-polyacrylamide gel electrophoresis and immunoblotting.
Rabbit Immunization—400 mg of purified recombinant protein were
injected subcutaneously into a rabbit four times at 2-week intervals.
Ten days following the last injection, high titer sera were obtained from
the rabbit. The sera were depleted of anti-GST antibodies by chroma-
tography on GST-bound nickel columns.
Immunoelectron Microscopy—P. falciparum parasites and parasite-
infected cells or tissues were fixed for 30 min at 4 °C with 1% formal-
dehyde, 0.1% glutaraldehyde in a 0.1 M phosphate buffer, pH 5 7.4.
Fixed samples were washed, dehydrated and embedded in LR White
resin (Polysciences, Inc.). Thin sections (70–80 nm) were blocked in a
phosphate buffer containing 5% w/v nonfat dry milk and 0.01% v/v
Tween 20 (21). Grids were incubated at 4 °C overnight in solutions
containing variable concentrations of rabbit antiserum reactive to do-
main-specific recombinant proteins diluted in the blocking buffer. Pre-
immune sera were used as negative controls. After washing, grids were
incubated for 1 h in 15 nm gold-conjugated goat anti-rabbit IgG (Am-
ersham Pharmacia Biotech) diluted 1:40 in phosphate buffer containing
1% bovine serum albumin and 0.01% Tween 20. Following the 1-h
incubation, grids were rinsed with phosphate buffer containing 1%
bovine serum albumin and 0.01% Tween 20 and fixed with glutaralde-
hyde to stabilize the gold particles. Samples were stained with uranyl
acetate and lead citrate and examined by electron microscopy.
Immunoblot Analysis—Protein extracts from parasites were pre-
pared by boiling them in sample buffer for 10 min (22). For the sporo-
zoite stage, parasites were isolated from dissected salivary glands of
infected mosquitoes. For the asexual blood stages, parasites were ob-
tained from a saponin lysis of infected red blood cells grown in culture
(23). Protein extracts were fractionated on 8% SDS-polyacrylamide gel
electrophoresis and transferred onto nitrocellulose membranes. The
membranes were incubated in rabbit antiserum diluted 1:500 for 1 h.
Horseradish peroxidase-conjugated anti-rabbit IgG was used to detect
positive signals using the ECL kit (Amersham Pharmacia Biotech).
Preimmune sera and lysates from uninfected human red blood cells
were used as negative controls.
RESULTS
Library Construction—To evaluate the efficiency of CS de-
pletion in the subtracted cDNA library, 100 ng of the recovered
single-stranded cDNA were amplified with oligonucleotide
primers complementary to the cloning vector to generate a
heterogeneous mixture of fragments of 200–1000 bp in size.
The products were amplified again with gene-specific primers.
Although two marker genes, TRAP (24, 25) and P2 (26), were
detected, no signal corresponding to the CS gene was amplified,
indicating that the subtraction technique was highly efficient
(data not shown). The amplification products were subcloned
into the UniZap vector and packaged in l phage, producing a
library of 1.45 3 106 primary phage.
Library Screening, Southern and Northern Analyses of
MB2—A screening of 1 3 104 primary phage with the human
volunteer serum led to the selection of 18 candidate phage
clones. These were rescreened, and 12 phage again were reac-
tive for antibodies. Southern analyses showed that 1 of the 12
secondary clones hybridized specifically to P. falciparum
genomic DNA and showed patterns of hybridization consistent
with a single-copy gene (Fig. 1A). This 496-bp sporozoite cDNA
clone was designated spz-MB2 and was selected for further
characterization. Northern analyses of RNA isolated from2 W. O. Rogers, unpublished data.
FIG. 1. Southern and Northern analyses of the MB2 gene and
transcription product. A, Southern blot of P. falciparum genomic
DNA, strain FCR3, digested with various restriction enzymes and hy-
bridized with the spz-MB2 cDNA clone. Lane 1, EcoRI/HindIII; lane 2,
PstI/HindIII; lane 3, PstI/EcoRI; lane 4, PstI/EcoRV; lane 5, PstI/NdeI.
B, Northern blot of P. falciparum blood-stage mRNA hybridized with a
probe derived from nucleotides 1–580 of the MB2 ORF. The lane con-
tained 20 mg of total RNA. The approximate locations of molecular size
markers in kilobases (kb) are indicated to the right of each of the panels.
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blood-stage parasites cultured in vitro and hybridized with
probes derived from both the 59 and 39 ends of the complete
ORF (described below) produced a single positive signal at ;7.5
kilobases (Fig. 1B).
Sequence Analysis of the MB2 cDNA and Gene—A compari-
son of the size of the spz-MB2 cDNA with the mRNA detected
in the Northern analyses indicates that it is not a full-length
cDNA. Furthermore, primary sequencing of spz-MB2 showed
that it lacked a translation termination codon and represented
an incomplete ORF. Sequence complementary to MB2 was
detected in an asexual blood-stage cDNA library using specific
gene amplification primers, and therefore the library was
screened with the spz-MB2 cDNA. Two overlapping blood-stage
cDNAs, c3–1-18 and c18–4-23, were identified (Fig. 2A). Nu-
cleotide sequence analysis revealed that the reading frame of
spz-MB2 was contained entirely within a contig formed by
these two cDNAs. The c3–1-18 clone contained a putative
translation initiation codon and a 435-bp 59 end untranslated
region (UTR). The 39 end termini of the c3–1-18 and c18–4-23
cDNAs each have what appear to be polyadenylation (poly(A))
sequences characteristic of the 39 end termini of processed
mRNAs. However, there were no translation termination
codons located to the 59 end of the poly (A) tracks in either of
the cDNAs, and the overlap of c3–1-18 with c18–4-23 revealed
that the 17 terminal A nucleotides in c3–1-18 comprise an
internal A-rich nucleotide stretch in c18–4-23. Therefore, we
concluded that the oligo(dT) primed the mRNA for cDNA syn-
thesis from within the coding region.
To obtain additional 39 end sequence of MB2, a Sau3AI
genomic library (strain ITO) was screened using as a probe the
400 nucleotides at the 39 end of c18–4-23. A genomic clone,
g2–4-4#5, was identified having overlapping and contiguous
sequence with c18–4-23. The sequence of g2–4-4#5 confirmed
that the 17-A region at the 39 end of c18–4-23 is an internal
A-rich nucleotide track, supporting the conclusion that these
A-rich internal nucleotide tracks were primed by oligo(dT). To
obtain additional 39 end cDNA sequence, the 600 nucleotides at
the 39 end of g2–4-4#5 were used to screen the blood-stage
cDNA library, resulting in the identification of the cDNA clone,
c3–4-29. Sequencing of c3–4-29 revealed that it was contiguous
FIG. 2. Structure of the MB2 gene and expression products. A, schematic representation of cDNA and genomic clones used to identify and
assemble a cDNA containing the complete ORF of the MB2 gene. The cDNAs, spz-MB2, c3–1-18, c18–4-23, and c3–4-29, are represented as
horizontal lines above a linear representation of the full-length MB2 cDNA. The numbers above each cDNA refer to the terminal nucleotide
positions in the completed cDNA. The As in parentheses in the cDNA clones represent the internal and terminal priming poly(A) sites of the
oligo(dT) primers. The full-length cDNA is represented as a horizontal line numbered with the positions of the translation initiation (ATG) and
translation termination (TAA) codons, and the beginning and end of the sequence. The 59 end untranslated region (59-UTR) and polyadenylation
sequences (A) also are indicated. The three horizontal lines at the bottom denote the MB2 genomic clones, g2–6-8, g2–4-4#5, and g6–2-2. The
locations of the terminal nucleotides with respect to the cDNA are indicated above each line. Four horizontal arrows (a–d) represent the orientation
and approximate location of gene amplification primers used to verify the contiguity of the sequence in the parasite genome. B, schematic
representation of the MB2 protein sequence. The three domains, basic (B), acidic (A), and GTP-binding (G), are indicated as blocks with the
junctions of the domains numbered below. The amino (H2N) and carboxyl (COOH) ends are labeled. The four short horizontal lines represent the
approximate extents of the polypeptides, MB2-B, MB2-C, MB2-FA, and MB2-IF2, used to generate antibodies. C, primary amino acid sequence of
the conceptual translation of the MB2 gene. Amino acids in bold represent the putative signal peptide; bold and boxed, putative nuclear localization
sequences; bold and italicized, repeat regions with a single repeat unit underlined; bold and underlined, cell-surface retention sequence; italicized
and boxed, motifs conserved in the G domain.
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with c18–4-23. In addition, there are three stop codons at the
39 end of c-3–4-29, commencing at nucleotides 5266, 5272, and
5293, and there is a putative poly(A) region near the 39 end of
the last stop codon. The positions of the stop codons and the
authenticity of the poly(A) of the MB2 cDNA were supported by
the genomic clone, g6–2-2, identified by screening the genomic
library with a probe derived from the 39 end of c3–4-29. Simi-
larly, the 59 end UTR and the start codon of MB2 also were
verified by the clone g2–6-8, isolated from the genomic library
using a probe derived from the 59 end of c3–1-18. The overlap-
ping primary sequences of the three blood-stage cDNA clones
and the contiguity of their reading frames allowed us to assem-
ble a complete ORF of MB2 that is 4830 nucleotides in length,
of which 77% of the bases are A-T pairs (data not shown). No
nucleotide polymorphisms were observed among the cDNA and
genomic sequences, indicating that there is a single allele of the
MB2 gene encoded and expressed in the parasite strains used
in our analyses.
Because the nucleotide sequences of the three genomic clones
did not overlap, we designed gene amplification primers a, b, c,
and d (Fig. 2A) to assess the contiguity of the MB2 gene in the
parasite genome. Amplification products produced by the
primer pairs a1b and c1d with parasite genomic DNA as the
template gave the predicted product sizes, ;700 and ;1000 bp,
respectively (data not shown), indicating that MB2 is organized
as a contiguous, single-exon gene in the parasite genome.
Sequence Analysis of the MB2 Putative Translation Prod-
uct—MB2 encodes a putative translation product that is 1610
aa in length with an approximate molecular mass of 187 kDa
(Fig. 2, B and C). The predicted protein is rich in asparagine
(15%) and lysine (13%) and is strongly basic with a calculated
net charge of 120 at pH 7 and a pI of 8.3. The primary amino
acid sequence can be separated into three distinct, linear do-
mains, the first of which is an amino-terminal basic domain of
490 residues (aa 1–490) with a calculated net charge of 130
and a pI of 9.4. We have designated this the “B” domain. This
domain contains a region of six 9-aa imperfect repeats (aa
211–264) with the consensus sequence L, N, S, K, K, N, D/N, N,
T/S. The central acidic domain, designated “A,” encompasses
496 residues (aa 491–986) with a calculated net charge of 26.2
and a pI of 6.1. The boundary between the B and A domains
was selected to maximize the basic and acidic properties of the
respective domains. The A domain contains two regions of
imperfect repeats of 5 amino acids. The first region (aa 493–
542) contains 10 repeats with a consensus sequence of D, N,
Q/P, N, Y. The second region (aa 870–914) contains nine re-
peats with a consensus of I/M, N/D, V, Q, D. No similarities to
any sequences of known function deposited in the data bases
FIG. 3. Immunolocalization of the MB2 protein in different developmental stages of P. falciparum. A–D, sporozoite preparations. A
shows a cross-section of a sporozoite (S) in the mosquito salivary gland (Sg) reacted with anti-B domain antiserum. B is a cross-section of a free
sporozoite reacted with anti-A domain antiserum. C and D are partial-oblique and cross sections (respectively) of sporozoites in HepG2-A16 cells
(He) reacted with anti-B and anti-A domain antisera, respectively. PV is the parasitophorous vacuole space. E–G, asexual stage parasite
preparations. E is a cross-section of a trophozoite in an erythrocyte (E), showing localization principally to the parasite nucleus (N) and some in
the parasite cytoplasm (Pc). F is a section of schizonts showing MB2 localization to the nucleus and some cytoplasm. Hemazoin (Hz) also is visible.
Both E and F were reacted with anti-B domain antiserum. G shows sections of parasites at the merozoite (Mz) stage reacted with anti-A domain
antiserum, showing only cytoplasmic localization. H and I, localization of MB2 in gametocytes (labeled G) reacted with anti-B and anti-A domain
antisera, respectively. MB2 can be detected in the nucleus, cytoplasm, and the PV space. Arrows indicate the location of gold particles. J,
localization of MB2 in the exoerythrocytic (EE) stages of an Aotus monkey hepatocyte (AH) reacted with anti-B domain antiserum. All bars are 0.5
mm in length.
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were detected for either the B or A domains. Finally, a 624-
residue carboxyl-terminal domain (aa 987–1610) with sequence
similarity to the GTP-binding domain of the prokaryotic trans-
lation initiation factor 2, IF2, as revealed by the BLAST search
program (27) has been designated “G.” The boundary between
the A and G domains was selected based on the start of the
regions of similarity of the MB2 protein with known IF2 mol-
ecules. In contrast to its overall hydrophilic nature, the MB2
polypeptide contains at the amino terminus a strongly hydro-
phobic region (aa 1–25) mapped by a Kyte-Doolittle hydropho-
bicity plot. The PSORT computer program (28) predicted an
uncleavable signal peptide in the hydrophobic amino-terminal
region of MB2. However, the SignalP program (29) predicted
that the signal peptide could be cleaved between a pair of S-S
residues at aa 27–28 (Fig. 2C). Currently, we have no experi-
mental data that support one alternative over the other. The
PSORT program also predicted a number of nuclear localiza-
tion signals (NLS), PKKK (aa 120–123), RRKK (aa 173–176),
KKKKK (aa 652–656), and a bipartite NLS, KKNKELPFNN-
KFKKIIK (aa 718–734), within the B and A domains. Multiple
putative sites for N-glycosylation, N-myristoylation, and phos-
phorylation were detected by the ScanProsite program (Ref. 30;
data not shown). There is a polybasic motif, KKKKKGKSRKK
(aa 956–966), just before the start of the G domain, that could
function as a plasma membrane localization signal as well as a
cell-surface retention sequence (CRS) (31). This sequence also
could be a putative NLS, although PSORT failed to identify it
as such. The similarity of the G domain to the GTP-binding
domains of the prokaryotic IF2 proteins includes the conserva-
tion of sequence and spacing of three motifs, GX4GK (aa 999–
1005), DX2K (aa 1046–1049), and NKXD (aa 1100–1104), com-
mon to this family of proteins (32). There is a small variation in
the third motif, TKXD, in MB2 as compared with the consensus
seen in other G proteins (Fig. 2C).
Ultrastructural Localization of MB2 Protein—Immunoelec-
tron microscopy (IEM) was used to study the subcellular local-
ization of the MB2 antigen. All rabbit antisera prepared
against recombinant peptides derived from the B and A do-
mains (Fig. 2A), and reacted with sectioned material contain-
ing sporozoites, showed that MB2 protein was localized pre-
dominantly to the surface (Fig. 3, A–D). This was true of
sporozoites in salivary glands (Fig. 3, A and B), as well as those
that invaded in vitro cells of the human liver cell line, HepG2-
A16 (Fig. 3, C and D). No antibody reaction was detected with
sporozoites using the anti-G domain antibody (data not shown).
Preimmune control sera for all reagents were negative (data
not shown).
In contrast, the majority of the MB2 protein detected in
blood-stage parasites using both antisera against the B domain
was localized in the nucleus, with some antibody reactivity
detected in the cytoplasm (Fig. 3, E and F) and data not shown).
Rabbit antisera against the A and G domains detected protein
only in the cytoplasm of these parasites (Fig. 3G and data not
shown). Furthermore, the numbers of gold particles observed in
sections of parasites exposed to antibodies against the A and G
domains were low when compared with the signal produced by
the anti-B domain antisera, indicating probably that the ma-
jority of MB2 protein present at the blood stages does not
contain the A and G domains.
MB2 protein was detected in the cytoplasm, nucleus, and
parasitophorous vacuole (PV) space of gametocyte-stage para-
sites using the anti-B domain antiserum (Fig. 3H). MB2 pro-
tein detected by the anti-A domain antiserum was localized
only in the PV space (Fig. 3I), indicating that the protein
detected in the nucleus and cytoplasm with the anti-B domain
antiserum does not contain the A domain. The anti-G domain
antiserum produced a high background signal, making it diffi-
cult to interpret any specific localization pattern.
Finally, we attempted to use IEM to look at the localization
of MB2 protein in the exoerythrocytic stages of the parasite. A
section of the liver of an infected Aotus monkey was reacted
with the anti-B domain antiserum. It is hard to locate the
parasites in these sections, but we were able to find some that
revealed that the protein is localized mostly in the cytoplasm
with some in the PV space (Fig. 3J). Sections reacted with the
anti-A domain antiserum had high backgrounds obscuring any
evidence of a specific localization pattern.
Immunoblot Analyses—A series of immunoblotting experi-
ments were performed with parasite protein extracts prepared
from the sporozoite and blood stages to determine the relative
size of the MB2 protein (Fig. 4). Both anti-B and anti-A domain
antisera detected a single polypeptide of ;120 kDa at the
sporozoite stage (Fig. 4, A and B). No immunoblot analyses
were done on sporozoite preparations with anti-G domain an-
tiserum because of the negative results obtained in the IEM
analyses. Immunoblotting using anti-B domain antibody de-
tected a single polypeptide of ;66 kDa at the blood stages (Fig.
4C). Furthermore, the 66-kDa polypeptide was not detected
with either the anti-A or anti-G domain antibodies (Fig. 4D and
data not shown). These data are consistent with the IEM study
and indicate that the MB2 polypeptide located at the surface of
sporozoites consists of only the B and A domains, and the
polypeptide translocated into the nucleus of parasites at the
blood stages consists primarily of the B domain.
DISCUSSION
A major difficulty in immunoscreening of expression librar-
ies to identify P. falciparum sporozoite antigens is the abun-
dant and immunodominant characteristics of the CS protein.
The abundant expression of the CS gene results in its repre-
sentation in high frequency in cDNA libraries (15), and its
immunodominant repeat domain induces a high antibody titer
in the host providing the screening antiserum (7). Thus, to
identify novel, non-CS antigens, we depleted the CS sequence
from a sporozoite cDNA expression library prior to screening.
The effectiveness of this approach was demonstrated by the
isolation of MB2, a gene encoding a novel antigen with stage-
dependent localization.
The Southern analyses revealed that MB2 is present in the
parasite genome most likely as a single-copy gene. The nucle-
otide sequence data indicated that it consists of a single exon
and is represented most likely in our parasite samples by a
FIG. 4. Immunoblot analysis of protein extracts of P. falcipa-
rum sporozoite and blood stages. A and B, protein extracts prepared
from sporozoites recovered from salivary glands of infected mosquitoes.
C and D, proteins extracts prepared from asexual blood-stage parasites.
A and C were probed with anti-B domain (MB2-B) antiserum; B and D
were probed with anti-A domain (MB2-FA) antiserum. The molecular
size markers (in kDa) are indicated to the left of each figure, and arrows
to the right mark the locations of the MB2 polypeptides.
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single allele. The Northern analyses with mRNA obtained from
the blood-stage parasites indicated that MB2 is expressed as a
single large transcript. We do not know if this size is common
to the other developmental stages of the parasite because of the
difficulty in obtaining sufficient mRNA for blotting experi-
ments. However, because the gene is single-copy and contains
no intron, it is unlikely that multiple transcripts are produced,
resulting either from expression of different genes or alterna-
tive splicing of a single gene. Thus, it is likely that the single-
transcript expression of MB2 is common to other developmen-
tal stages.
The overall length of the reconstructed MB2 cDNA is 2.2
kilobases smaller than the RNA species detected in the North-
ern analyses. This difference results most likely from large 59
end, and perhaps 39 end, untranslated regions. Although we
have neither a single genomic nor cDNA clone that spans the
entire ORF of MB2, based on the overlapping primary sequence
of the cDNA clones, the contiguity of their reading frames, and
the gene amplification analyses of the genomic clones, we are
confident that we have the complete expressed sequence of the
MB2 gene.
The complete ORF of MB2 predicts a full-length protein of
187 kDa. However, there are many predicted sites for post-
translational modification by myristoylation, glycosylation and
phosphorylation. Therefore, it is likely that the actual molecu-
lar weight of the primary protein structure is increased by
processing of individual amino acids. The predicted MB2 pro-
tein is rich in asparagine (15%) and lysine (13%), and therefore
is strongly basic. Asparagine is the most commonly used
(;12%) amino acid in P. falciparum, followed by lysine and
glutamic acid (;10%) (33, 34). Two other sporozoite surface
proteins, CS and the sporozoite-threonine-and-asparagine-rich
protein (STARP) (35), contain 29% and 25% asparagine, respec-
tively. It has been speculated that asparagine-rich motifs in the
amino acid sequence might be targets of opsonizing antibodies,
promoting parasite phagocytosis by immune cells (36–38).
Whether the MB2 protein is a target of opsonizing antibodies is
not known, but it is recognized by the immune serum of a
human volunteer protected by the irradiated sporozoite
vaccine.
Unlike a number of characterized Plasmodium genes that
are active only in certain stages, the MB2 gene is expressed in
many developmental stages of the parasite life cycle. However,
the MB2 gene product has differential localization throughout
development. The stage-dependent differential localization of
the MB2 protein suggests strongly that it has a multifunctional
role during development of the parasites. It is conceivable that
it functions as a signal recognition molecule while it is on the
surface of the sporozoites. It then may transmit a signal to the
nucleus by migrating there during the blood stages. Once in-
side the nucleus, it may function in the regulation of gene
expression, participating in the process of turning off genes
that are not required and activating genes that are required for
blood stage infection. Examples of genes that are known to be
inactivated as the parasite develops to the blood-stage are CS
(39–40) and TRAP (25), and genes that are activated are mer-
ozoite surface protein genes, MSPs (41).
In gametocytes, the protein product is localized in the nu-
cleus, cytoplasm, and the PV space. This differential localiza-
tion may indicate that the MB2 gene product is in a transi-
tional phase from its functional role in the nucleus to the cell
surface or it may have a role in the development of the sexual
stages of the parasite. In the exoerythrocytic stage, the MB2
protein detectable by anti-B domain antisera is localized
mainly in the cytoplasm, although some can be detected in the
PV space. As with the gametocytes, this expression may be a
transitional phase in the specific localization as the parasite
develops in the liver. The expression of MB2 in this stage is
important potentially as a vaccine target since the hepatocyte
expresses major histocompatibility complex molecules that can
be recognized by T cells. Research in the last 10 years has
indicated that the infected hepatocyte can be an important
target for immune attack (11).
Although the MB2 protein is localized on the surface mem-
brane of sporozoites, the primary amino acid sequence contains
no apparent transmembrane domain or glycosylphosphatidyli-
nositol anchor signal. However, the amino acid sequence does
contain a polybasic motif that was shown to function as plasma
membrane localization signal as well as CRS motif (31, 42).
Many cytokines are retained on the membrane surface of the
producer cell in a process mediated by the CRS. Studies have
shown that, if the basic amino acids are deleted or mutated to
acidic or neutral amino acids, then the membrane localization
of the protein is affected (43, 44). Therefore, we predict that the
polybasic motif is the most likely domain used to localize the
MB2 product to the membrane surface of sporozoites.
We provide evidence supporting the conclusion that protein
processing is the mechanism by which MB2 regulates its dif-
ferential cellular localization (Fig. 5). The MB2 protein is lo-
calized mostly to the surface membrane of sporozoites as a
;120-kDa species consisting of the B and A domains (Figs. 3 (A
and B) and 5A). It is important to note that the predicted
molecular mass of the B and A domains combined is ;116 kDa.
This similarity in molecular mass of the actual protein and the
FIG. 5. Summary of expression and localization data for the
MB2 protein. Each panel (A–D) lists the stage of the parasite (first
line) and the molecular size determination based on immunoblotting
(second line). The third line indicates which domains were detected in
either the immunoblotting or immune electron microscopy experiments.
The immune electron micrographs are excerpted from Fig. 4. The as-
terisks in B and D indicate that the molecular size is not confirmed by
immunoblotting analyses. The question mark (?) in D indicates that the
presence of the G domain could not be unequivocally confirmed. All
abbreviations are as in Figs. 3 and 4.
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predicted domains is remarkably close and does not take into
consideration the effects of post-translational changes to spe-
cific amino acids or the arbitrary boundaries assigned to the
domains. As the sporozoites invade hepatocytes represented by
the human cultured liver cells, the B and A domains of the MB2
protein are still detectable on the membrane surface (Figs. 3 (C
and D) and 5B). We do not have immunoblot data for this stage,
but we infer from the IEM study that the size of the protein is
most likely ;120 kDa, similar to the size detected in free
sporozoites. As the parasite develops to the blood stages, the
majority of MB2 protein detected inside the parasite nucleus
consists only of the B domain and is represented in immunob-
lots by a ;66-kDa species (Figs. 3 (E and F) and 5C). The
predicted molecular mass, ;57 kDa, of the B domain selected
by our analysis of the amino acid primary structure, is consist-
ent with this smaller size polypeptide. As the parasite differ-
entiates to gametocytes, the MB2 protein is found in the PV
space as well as the nucleus and cytoplasm (Figs. 3 (H and I)
and 5D). Based on the different labeling patterns seen with the
anti-B and anti-A domain antisera, it is likely that the signal in
the cytoplasm and nucleus originates from the ;66-kDa moi-
ety. The protein in the PV space contains at least the B and A
domains, and may contain the G domain. However, as noted in
the results, the IEM study using the anti-G domain antibody is
inconclusive, and we do not have immunoblot data that would
provide the size of MB2 for the gametocyte stage.
We propose that the MB2 protein detected weakly in the
cytoplasm of blood-stage parasites by the anti-A and anti-G
domain antisera most likely represents the full-length, newly
synthesized MB2 protein that has not been processed proteo-
lytically into the ;66-kDa polypeptide. We propose further that
the full-length MB2 protein is processed specifically at the
sporozoite stage to the ;120-kDa polypeptide during synthesis
and/or cellular trafficking. The ;120-kDa species contains the
polybasic CRS-like motif, allowing it to be preferentially re-
tained on the surface of the sporozoite. The secondary or high-
er-order structure of the ;120-kDa protein may conceal the
NLS in the B and A domains. At the blood stage, the full-length
MB2 protein is processed specifically into the ;66-kDa
polypeptide as supported by the absence of the ;120-kDa spe-
cies. The processing of the MB2 protein into the ;66-kDa
polypeptide would remove the polybasic motif, thus removing
the membrane targeting signal, and perhaps this processing
exposes the nuclear localization signals allowing the ;66-kDa
polypeptide to translocate to the nucleus. Finally, MB2 protein
in the gametocyte stage may be processed into at least two
forms, one of which consists of at least the B and A domains and
is exported to the PV space. The other form, consisting most
likely of only the B domain, is transported to the nucleus.
Another interesting feature of the MB2 protein is the G
domain, which has significant sequence similarity to the pro-
karyotic IF2. Our data indicated that the G domain is not
present in the MB2 protein detected on the sporozoite surface,
nor is it present in the nucleus at the blood stages. It is con-
ceivable that the cleavage of the MB2 protein requires energy,
and this requirement is fulfilled by the G domain since it can
bind to GTP. The cleavage process most likely includes removal
of the G domain as evidenced by the inability to detect it with
specific antiserum in most stages of the parasite. Alternatively,
because MB2 can bind potentially to GTP, it is possible that
there are conformational differences between the GTP-bound,
GDP-bound, and unbound states that can regulate the distinct
proteolytic processing of the MB2 protein.
In the last two decades, research efforts to develop recombi-
nant vaccines against malaria have yielded largely limited
successes. Although we have made significant progress in un-
derstanding immune responses and identifying a number of
antigens, we are still not certain as to which host immune
mechanisms and target antigens are relevant to protective
immunity. In particular, the parasite antigenic composition at
the sporozoite stage is still largely unknown. Because of the
complexity of the Plasmodium species, we do not know if we
have reached the heart of its antigenic repertoire required for
identifying antigens that are relevant to protection or we are
still wandering at the periphery, being misled by a limited
number of identified antigens. However, vaccine development
remains a viable option because it is clear that sterile immu-
nity can be experimentally induced in humans (3). We believe
that an optimal malaria vaccine would need to target multiple
stages of the parasite life cycle, including the sexual stages
developed inside the invertebrate host. As more novel antigens
are being characterized, it is our expectation that the knowl-
edge acquired from them can bridge the gap between recombi-
nant and sporozoite-attenuated vaccines.
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